“Instead of focusing on money, you talk openly about ‘value,’ Well, what is that? Or it’s all about ‘relationships.’ The industry talks partnership in public, but behind closed doors, aren’t prices and costs closing or breaking outsourcing business deals?”
Moderator, Outsourced Pharma San Diego, 2016.
Louis Garguilo, OutsourcedPharma chief editor focused his attention on discussion from the 2016 San Diego Outsourced Pharma event in his recent editorial, The Price At My CMO Isn’t Right … But How Do I Know? and panel guests left no molten rock uncovered.
Improving partnerships, smarter procurement procedures, streamlined supply chains, improved partnerships … despite these efforts and some good results, our costs to develop and manufacture drugs still seems to go up, while the pressure to reduce drug prices bubbles up to the surface. Your CEO – and society – is looking for maximum efficiency from all parts of your business.
Join us for further discussion at the panel, Costs and price pressures rise…. best efforts notwithstanding and take a hard look at the structural, systemic and other financial inputs into your outsourcing. Join the following panelists to discuss this topic in more detail:
- George Avgerinos, Sr. VP Operations | Fortress Biotechnology
- Susan Dexter, Managing Director | Latham Biopharm
- Anand Ekambaram, Executive Director, Global Technical Operations | Merck
- BJ Hull, VP/GM | Emergent BioSolutions
- Brian James, SVP Operations | Rondaxe Pharma(Moderator)